DiscoverBiotech CEO SisterhoodIvana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership
Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership

Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership

Update: 2025-08-19
Share

Description

Interviewed by Xilio Therapeutics President & CEO René Russo, Dr. Liebisch describes her start in the industry as a patent attorney, discusses why having a champion in a larger partner is key, and explains why she even once threw a party when Vigil discontinued a candidate. Vigil Neuroscience was acquired by Sanofi earlier this year for an equity value representing approximately $470 million, plus a CVR.

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership

Ivana Liebisch on her career path, the successful sale of Vigil to Sanofi, moving quickly and decisively on decisions, and her thoughts on leadership

BiotechTV